Treatment of Alzheimer’s Disease with Clioquinol
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
As heavy metal ions may be implicated in the formation of senile plaques in Alzheimer-afflicted brains, treatment with clioquinol was tested in 20 patients with Alzheimer’s disease. Clioquinol is a chelator that crosses the blood-brain barrier and has greater affinity for zinc and copper ions than for calcium and magnesium ions. Treatment was given for 21 days at doses of 20 mg/day to 10 patients and 80 mg/day to another 10 patients. The study was blind to the dosages but included no controls. Cerebrospinal fluid (CSF) investigations revealed a significant increase at day 7 and a decrease at day 21 in Tau protein and growth-associated protein (GAP43). These proteins are increased in Alzheimer’s disease and considered as rather stable markers. The initial increase may indicate a temporary cytotoxicity to the brain and/or an increased release into the CSF from stores in the tissue, possibly from senile plaques where the proteins are accumulated. The levels of CSF-Tau protein correlated positively and significantly with the serum levels of copper and also with the serum copper/zinc ratio. Clinical ratings showed slight improvement after 3 weeks treatment with clioquinol in this open study.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nevertheless, iron chelators have demonstrated therapeutic benefits in Alzheimer's [1674,1710,1769-1771], Parkinson's [1037,1729,1772], cold-induced brain injury [1773,1774], coronary disease [714,797], renal diseases [1775], various kinds of infection [1763] and of course in iron overload diseases [1762,1767].”
From Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases (2009) · cites this paper as [1771]
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
Rapid induction of Alzheimer A beta amyloid formation by zinc
Bush, A., Pettingell, W., Multhaup, G., d Paradis, M., Vonsattel, J., Gusella, J., Beyreuther, K., Masters, C., & Tanzi, R. (1994) · Science · doi:10.1126/science.8073293 · Cited by 1,522
Atwood, C. S., Moir, R. D., Huang, X., Scarpa, R. C., Bacarra, N. M. E., Romano, D. M., Hartshorn, M. A., Tanzi, R. E., & Bush, A. I. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.21.12817 · Cited by 1,009
Blennow, K., Wallin, A., Ågren, H., Spenger, C., Siegfried, J., & Vanmechelen, E. (1995) · Molecular and Chemical Neuropathology · doi:10.1007/bf02815140 · Cited by 789
Self-citationIntramuscular desferrioxamine in patients with Alzheimer's disease
MCLACHLAN, D. (1991) · The Lancet · doi:10.1016/0140-6736(91)92978-b · Cited by 764
Andreasen, N., Hesse, C., Davidsson, P., Minthon, L., Wallin, A., Winblad, B., Vanderstichele, H., Vanmechelen, E., & Blennow, K. (1999) · Archives of Neurology · doi:10.1001/archneur.56.6.673 · Cited by 660
Self-citationThe Alzheimer's disease assessment scale: an instrument for assessing treatment efficacy.
Mohs, R. C., Rosen, W. G., & Davis, K. L. (1983) · PubMed · Cited by 425
Primary structure and transcriptional regulation of GAP-43, a protein associated with nerve growth
Basi, G. S., Jacobson, R. D., Virág, I., Schilling, J., & Skene, J. H. P. (1987) · Cell · doi:10.1016/0092-8674(87)90616-7 · Cited by 355
Cited by
Metals in Neurobiology: Probing Their Chemistry and Biology with Molecular Imaging
Que, E. L., Domaille, D. W., & Chang, C. J. (2008) · Chemical Reviews · doi:10.1021/cr078203u · Cited by 2,061
The neurobiology of zinc in health and disease
Frederickson, C. J., Koh, J.-Y., & Bush, A. I. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1671 · Cited by 1,850
“( Figs 4 and 5 ), and early-phase clinical trials indicate that zinc chelation inhibits Aβ-plaque depositio”
BackgroundThe metallobiology of Alzheimer's disease
Bush, A. I. (2003) · Trends in Neurosciences · doi:10.1016/s0166-2236(03)00067-5 · Cited by 1,315
“CQ has now proceeded into Phase I [ 66 ] and Phase II clinical trials in individuals with AD.”
BackgroundRitchie, C. W., Bush, A. I., Mackinnon, A., Macfarlane, S., Mastwyk, M., MacGregor, L., Kiers, L., Cherny, R., Li, Q.-X., Tammer, A., et al. (2003) · Archives of Neurology · doi:10.1001/archneur.60.12.1685 · Cited by 988
Self-citationCopper, oxidative stress, and human health
Uriu-Adams, J. Y., & Keen, C. L. (2005) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2005.07.015 · Cited by 975
“Based on the concept that Cu has a role in the progression of AD, clinical trials have been initiated with the Cu chelating agent clioquinol (Regland et al., 2001; Ritchie et al., 2003).”
BackgroundBioinorganic Chemistry of Alzheimer’s Disease
Kepp, K. P. (2012) · Chemical Reviews · doi:10.1021/cr300009x · Cited by 672
Kell, D. B. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-2 · Cited by 554
“Nevertheless, iron chelators have demonstrated therapeutic benefits in Alzheimer’s [1509; 1541; 1598-1600], Parkinson’s [928; 1560; 1601], cold-induced brain injury [1602; 1603], coronary disease [621; 694], renal diseases [1604], various kinds of infection [1592] and of course in iron overload diseases [1591; 1596].”
BackgroundInfluentialCopper in the brain and Alzheimer’s disease
Hung, Y. H., Bush, A. I., & Cherny, R. A. (2010) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-009-0600-y · Cited by 498
Sparks, D. L., & Schreurs, B. G. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1832769100 · Cited by 459
Brain Insulin Resistance and Deficiency as Therapeutic Targets in Alzheimers Disease
M. de la Monte, S. (2012) · Current Alzheimer Research · doi:10.2174/156720512799015037 · Cited by 448
“However, in a later uncontrolled clinical trial of Clioquinol therapy for AD, the subjects showed only modest improvements in clinical ratings [402].”
BackgroundADAMs family members as amyloid precursor protein α‐secretases
Allinson, T. M. J., Parkin, E. T., Turner, A. J., & Hooper, N. M. (2003) · Journal of Neuroscience Research · doi:10.1002/jnr.10737 · Cited by 440
“Studies in mice (Cherny et al., 2001) as well as preliminary studies in humans (Regland et al., 2001) have shown promising results using clioquinol, an antibiotic that selectively chelates zinc and copper and is capable of crossing the blood-brain barrier.”
BackgroundResultRedox‐Active Metals, Oxidative Stress, and Alzheimer's Disease Pathology
HUANG, X., MOIR, R. D., TANZI, R. E., BUSH, A. I., & ROGERS, J. T. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1306.012 · Cited by 425
Daniel, K. G., Chen, D., Orlu, S., Cui, Q. C., Miller, F. R., & Dou, Q. P. (2005) · Breast Cancer Research · doi:10.1186/bcr1322 · Cited by 326
“CQ has been investigated for use in Alzheimer's disease in regards to its ability to bind to copper found in amyloid plaques [43,47-50].”
Di Vaira, M., Bazzicalupi, C., Orioli, P., Messori, L., Bruni, B., & Zatta, P. (2004) · Inorganic Chemistry · doi:10.1021/ic0494051 · Cited by 292
Atwood, C. S., Obrenovich, M. E., Liu, T., Chan, H., Perry, G., Smith, M. A., & Martins, R. N. (2003) · Brain Research Reviews · doi:10.1016/s0165-0173(03)00174-7 · Cited by 293
Biological metals and Alzheimer's disease: Implications for therapeutics and diagnostics
Duce, J. A., & Bush, A. I. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.04.003 · Cited by 283
Anticancer Activity of the Antibiotic Clioquinol
Ding, W.-Q., Liu, B., Vaught, J. L., Yamauchi, H., & Lind, S. E. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3577 · Cited by 248
“It proved nontoxic in a small Swedish trial ( 17 ) involving 20 patients.”
BackgroundClioquinol: Review of its Mechanisms of Action and Clinical Uses in Neurodegenerative Disorders
Bareggi, S. R., & Cornelli, U. (2012) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00231.x · Cited by 243
“An open study of various doses of clioquinol found an improvement in the cognitive test performance of AD patients [57], who also showed a decrease in CSF Tau protein levels, a marker that is usually increased in AD patients.”
BackgroundCostello, L. C., & Franklin, R. B. (2016) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2016.04.014 · Cited by 242
Huang, X., Atwood, C. S., Moir, R. D., Hartshorn, M. A., Tanzi, R. E., & Bush, A. I. (2004) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-004-0602-8 · Cited by 242
Zinc takes the center stage: its paradoxical role in Alzheimer’s disease
Cuajungco, M. P., & Fagét, K. Y. (2003) · Brain Research Reviews · doi:10.1016/s0165-0173(02)00219-9 · Cited by 242
Novel solid-state sensor material for efficient cadmium(II) detection and capturing from wastewater
Shahat, A., Kubra, K. T., Salman, M. S., Hasan, M. N., & Hasan, M. M. (2021) · Microchemical Journal · doi:10.1016/j.microc.2021.105967 · Cited by 241
Elevation of serum copper levels in Alzheimer’s disease
Squitti, R., Lupoi, D., Pasqualetti, P., Dal Forno, G., Vernieri, F., Chiovenda, P., Rossi, L., Cortesi, M., Cassetta, E., & Rossini, P. M. (2002) · Neurology · doi:10.1212/wnl.59.8.1153 · Cited by 239
Chen, D., Cui, Q. C., Yang, H., Barrea, R. A., Sarkar, F. H., Sheng, S., Yan, B., Reddy, G. P. V., & Dou, Q. P. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3546 · Cited by 212
Current Status of Metals as Therapeutic Targets in Alzheimer's Disease
Finefrock, A. E., Bush, A. I., & Doraiswamy, P. M. (2003) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2003.51368.x · Cited by 204
Innocenti, A., Vullo, D., Scozzafava, A., & Supuran, C. T. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.01.077 · Cited by 198
Lee, J.-Y., Friedman, J. E., Angel, I., Kozak, A., & Koh, J.-Y. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.01.005 · Cited by 191
Observations on Screening-Based Research and Some Concerning Trends in the Literature
Baell, J. B. (2010) · Future Medicinal Chemistry · doi:10.4155/fmc.10.237 · Cited by 179
Excess of nonceruloplasmin serum copper in AD correlates with MMSE, CSF β-amyloid, and h-tau
Squitti, R., Barbati, G., Rossi, L., Ventriglia, M., Dal Forno, G., Cesaretti, S., Moffa, F., Caridi, I., Cassetta, E., Pasqualetti, P., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000223343.82809.cf · Cited by 180
A brief overview of amyloids and Alzheimer's disease
Ow, S., & Dunstan, D. E. (2014) · Protein Science · doi:10.1002/pro.2524 · Cited by 175
A Perspective – can copper complexes be developed as a novel class of therapeutics?
Wehbe, M., Leung, A. W. Y., Abrams, M. J., Orvig, C., & Bally, M. B. (2017) · Dalton Transactions · doi:10.1039/c7dt01955f · Cited by 173
Biomedical applications of copper ionophores
Oliveri, V. (2020) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2020.213474 · Cited by 169
Challenges Associated with Metal Chelation Therapy in Alzheimer's Disease
Hegde, M. L., Bharathi, P., Suram, A., Venugopal, C., Jagannathan, R., Poddar, P., Srinivas, P., Sambamurti, K., Rao, K. J., Scancar, J., et al. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-1068 · Cited by 167
“Few case studies and animal experimentation have been reported in this area [50–52]; however, no clinical evidence has been provided so far to support the use of chelating agents as an adjunctive treatment for AD or other neurodegenerative disorders with similar etiology.”
Metals in our minds: therapeutic implications for neurodegenerative disorders
Doraiswamy, P. M., & Finefrock, A. E. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00809-9 · Cited by 161
Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases
Lleó, A., Cavedo, E., Parnetti, L., Vanderstichele, H., Herukka, S. K., Andreasen, N., Ghidoni, R., Lewczuk, P., Jeromin, A., Winblad, B., et al. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.232 · Cited by 159
Self-citationNanoparticle and other metal chelation therapeutics in Alzheimer disease
Liu, G., Garrett, M. R., Men, P., Zhu, X., Perry, G., & Smith, M. A. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2005.06.006 · Cited by 158
“[18] B.”
BackgroundStorr, T., Merkel, M., Song-Zhao, G. X., Scott, L. E., Green, D. E., Bowen, M. L., Thompson, K. H., Patrick, B. O., Schugar, H. J., & Orvig, C. (2007) · Journal of the American Chemical Society · doi:10.1021/ja068965r · Cited by 156
Zinc and copper modulate Alzheimer Aβ levels in human cerebrospinal fluid
Altschul, D., Launer, L. J., Adlard, P. A., Cherny, R. A., Tsatsanis, A., Volitakis, I., Blennow, K., Petrovitch, H., White, L. R., & Bush, A. I. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.10.012 · Cited by 165
“It is therefore difficult to predict the consequent change in CSF Aβ levels in the short and long term, as illustrated by a phase 1 study with low doses of CQ showing CSF Aβ levels to rise at day 7 of treatment and then fall at day 21 [36].”
BackgroundSelf-citationMitochondrial iron homeostasis and its dysfunctions in neurodegenerative disorders
Mena, N. P., Urrutia, P. J., Lourido, F., Carrasco, C. M., & Núñez, M. T. (2015) · Mitochondrion · doi:10.1016/j.mito.2015.02.001 · Cited by 153
Lipid peroxidation in neurodegeneration: new insights into Alzheimerʼs disease
Arlt, S., Beisiegel, U., & Kontush, A. (2002) · Current Opinion in Lipidology · doi:10.1097/00041433-200206000-00009 · Cited by 151
Liu, G., Men, P., Kudo, W., Perry, G., & Smith, M. A. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.03.064 · Cited by 148
“Indeed, metal chelating compounds, such as desferrioxamine, ethylenediaminetetraacetic acid (EDTA), and iodochlorhydroxyquin (clioquinol), have been used to treat patients with AD and provided significant clinical improvement [12,40,41].”
BackgroundJiang, H., Taggart, J. E., Zhang, X., Benbrook, D. M., Lind, S. E., & Ding, W. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.06.032 · Cited by 147
“Because of promising data in animal studies, clioquinol has been administered in clinical trials for Alzheimer's disease without recurrence of SMON [11; 12], prompting cautious reevaluation of it use as a therapeutic agent.”
Non-Cholinergic Strategies for Treating and Preventing Alzheimer??s Disease
Doraiswamy, P. M. (2002) · CNS Drugs · doi:10.2165/00023210-200216120-00003 · Cited by 150
Astrocyte functions in the copper homeostasis of the brain
Scheiber, I. F., & Dringen, R. (2012) · Neurochemistry International · doi:10.1016/j.neuint.2012.08.017 · Cited by 151
“Application of the copper chelators clioquinol (Regland et al., 2001; Ritchie et al., 2003) and D-penicillamine (Squitti et al., 2002) have shown at best slight improvements in cognitive functions of Alzheimer’s disease patients.”
BackgroundPreliminary studies of a novel bifunctional metal chelator targeting Alzheimer's amyloidogenesis
Dedeoglu, A., Cormier, K., Payton, S., Tseitlin, K. A., Kremsky, J. N., Lai, L., Li, X., Moir, R. D., Tanzi, R. E., Bush, A. I., et al. (2004) · Experimental Gerontology · doi:10.1016/j.exger.2004.08.016 · Cited by 141
“Moreover, a mild cognitive improvement has been reported for a smallscale open study of 30 AD patients following a 3 week treatment regime with another metal-complexing agent— clioquinol (CQ) (Regland et al., 2001).”
InfluentialMetal ionophores – An emerging class of anticancer drugs
Ding, W., & Lind, S. E. (2009) · IUBMB Life · doi:10.1002/iub.253 · Cited by 155
“More recently, clioquinol has been used in clinical trials for the treatment of Alzheimer’s disease (41,42), and explored as a potential anticancer agent (25).”
The role of intracellular zinc release in aging, oxidative stress, and Alzheimer’s disease
McCord, M. C., & Aizenman, E. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00077 · Cited by 136
Design of iron chelators with therapeutic application
Zhou, T., Ma, Y., Kong, X., & Hider, R. C. (2012) · Dalton Transactions · doi:10.1039/c2dt12159j · Cited by 136
Metal exposure and Alzheimer’s pathogenesis
Liu, G., Huang, W., Moir, R. D., Vanderburg, C. R., Lai, B., Peng, Z., Tanzi, R. E., Rogers, J. T., & Huang, X. (2006) · Journal of Structural Biology · doi:10.1016/j.jsb.2005.12.011 · Cited by 135
Perry, G. L., Sayre, L. M., Atwood, C., Castellani, R. J., Cash, A., Rottkamp, C. A., & Smith, M. A. (2002) · CNS Drugs · doi:10.2165/00023210-200216050-00006 · Cited by 142
Metal protein attenuating compounds for the treatment of Alzheimer's dementia
Sampson, E. L., Jenagaratnam, L., & McShane, R. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005380.pub5 · Cited by 124
Zinc and Excitotoxic Brain Injury: A New Model
Frederickson, C. J., Maret, W., & Cuajungco, M. P. (2004) · The Neuroscientist · doi:10.1177/1073858403255840 · Cited by 127
Iron and Mechanisms of Neurotoxicity
Salvador, G. A., Uranga, R. M., & Giusto, N. M. (2011) · International Journal of Alzheimer’s Disease · doi:10.4061/2011/720658 · Cited by 123
“In addition, both animal and human studies with clioquinol have been found to reverse Aβ deposition, improve cognition, general behavior and health, and lower plasma Aβ levels [79, 82, 83].”
BackgroundClioquinol targets zinc to lysosomes in human cancer cells
Yu, H., Zhou, Y., Lind, S. E., & Ding, W. (2008) · Biochemical Journal · doi:10.1042/bj20081421 · Cited by 114
Pharmacological activity of metal binding agents that alter copper bioavailability
Helsel, M. E., & Franz, K. J. (2015) · Dalton Transactions · doi:10.1039/c5dt00634a · Cited by 123
RICHARDSON, D. R. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1306.026 · Cited by 104
Biological activity of synthetic ionophores: ion transporters as prospective drugs?
Alfonso, I., & Quesada, R. (2013) · Chemical Science · doi:10.1039/c3sc50882j · Cited by 114
Altered microglial copper homeostasis in a mouse model of Alzheimer’s disease
Zheng, Z., White, C., Lee, J., Peterson, T. S., Bush, A. I., Sun, G. Y., Weisman, G. A., & Petris, M. J. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06888.x · Cited by 101
“Moreover, clinical trials with clioquinol or its derivative, PBT2, were found to improve cognitive scores and reduce Ab levels in the cerebral spinal fluid of AD patients (Regland et al. 2001; Ritchie et al. 2003; Lannfelt et al. 2008).”
BackgroundDagda, R. K., & Banerjee, T. D. (2015) · Reviews in the Neurosciences · doi:10.1515/revneuro-2014-0085 · Cited by 106
“…receptor inhibitors, and caspase inhibitors has been developed but has demonstrated modest to no benefit in clinical trials for treating various brain degenerative disorders (Snow et al., 2010; Johansson et al., 2011; Bonelli and Wenning, 2006; Regland et al., 2001; Sampson et al., 2012).”
Amyloid plaques beyond Aβ: a survey of the diverse modulators of amyloid aggregation
Stewart, K. L., & Radford, S. E. (2017) · Biophysical Reviews · doi:10.1007/s12551-017-0271-9 · Cited by 102
“3g), a chelator of copper and zinc ions, was able to reduce plaque burden and memory loss in animal models (Cherny et al. 2001) and in early-stage human clinical trials (Regland et al. 2001).”
BackgroundCopper homeostasis and cuproptosis in central nervous system diseases
Zhu, Z., Song, M. S., Ren, J., Liang, L., Mao, G., & Chen, M. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-07206-3 · Cited by 119
“…s mice (R6/2) Inhibition of HTT aggregation and reduction of striatal atrophy [115] Clioquinol Twenty AD patients Reduces levels of CSF-Tau protein [155] 8-hydroxyquinoline Glioma Activates transcription factors in glioma cells and inhibits cell proliferation [156] 8-hydroxyquinoline AD Inhibits…”
Brain-Delivery of Zinc-Ions as Potential Treatment for Neurological Diseases: Mini Review
M. Grabrucker, A., Rowan, M., & C. Garner, C. (2011) · Drug Delivery Letterse · doi:10.2174/2210303111101010013 · Cited by 92
Disease-Modifying Therapies in Alzheimer???s Disease: How Far Have We Come?
ll, M. H., Berger, T., & Heneka, M. T. (2006) · Drugs · doi:10.2165/00003495-200666160-00004 · Cited by 107
Copper homeostasis and cuproptosis in health and disease
Yang, Y., Wu, J., Wang, L., Ji, G., & Dang, Y. (2024) · MedComm · doi:10.1002/mco2.724 · Cited by 131
The potential application of iron chelators for the treatment of neurodegenerative diseases
Hider, R. C., Roy, S., Ma, Y. M., Le Kong, X., & Preston, J. (2011) · Metallomics · doi:10.1039/c0mt00087f · Cited by 83
Copper and iron in Alzheimer's disease: a systematic review and its dietary implications
Loef, M., & Walach, H. (2011) · British Journal Of Nutrition · doi:10.1017/s000711451100376x · Cited by 95
“Initially, PBT-1 had been tested in twenty patients with mildto-moderate AD, who had received 20 or 80 mg clioquinol for 21 d((134)).”
BackgroundMethodInfluentialCui, Z., Bu, W., Fan, W., Zhang, J., Ni, D., Liu, Y., Wang, J., Liu, J., Yao, Z., & Shi, J. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.06.056 · Cited by 83
The prion protein and neuronal zinc homeostasis
Watt, N. T., & Hooper, N. M. (2003) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(03)00166-x · Cited by 93
Metals in alzheimer's disease: a systemic perspective
Squitti, R. (2011) · Frontiers in bioscience · doi:10.2741/3938 · Cited by 88
Webster, L., Groskreutz, D., Grinbergs-Saull, A., Howard, R., O’Brien, J. T., Mountain, G., Banerjee, S., Woods, B., Perneczky, R., Lafortune, L., et al. (2017) · Health Technology Assessment · doi:10.3310/hta21260 · Cited by 74
Chen, Z., Gu, Y., Song, X., Liu, Y., Peng, Y., & Liang, H. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.10.037 · Cited by 74
Konagaya, M., Matsumoto, A., Takase, S., Mizutani, T., Sobue, G., Konishi, T., Hayabara, T., Iwashita, H., Ujihira, T., Miyata, K., et al. (2003) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2003.11.007 · Cited by 71
Copper-mediated β-amyloid toxicity and its chelation therapy in Alzheimer's disease
Singh, S. K., Balendra, V., Obaid, A. A., Esposto, J., Tikhonova, M. A., Gautam, N. K., & Pöeggeler, B. (2022) · Metallomics · doi:10.1093/mtomcs/mfac018 · Cited by 72
Amyloid-β Metal Interaction and Metal Chelation
Cuajungco, M. P., Frederickson, C. J., & Bush, A. I. (2006) · Springer eBooks · doi:10.1007/0-387-23226-5_12 · Cited by 72
ZnT3 mRNA levels are reduced in Alzheimer's disease post-mortem brain
Beyer, N., Coulson, D. T., Heggarty, S., Ravid, R., Irvine, G. B., Hellemans, J., & Johnston, J. A. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-53 · Cited by 67
“A slight improvement in clinical ratings was observed in twenty AD patients after a three week treatment with clioquinol [25], and it reduced plasma Aβ42 levels and increased Zn2+ levels in a phase two clinical trial in AD [26].”
Metal Ion Signaling in Biomedicine
Rodriguez, R., Müller, S., Colombeau, L., Solier, S., Sindikubwabo, F., & Cañeque, T. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00577 · Cited by 76
Chen, D., & Dou, Q. P. (2008) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.6.739 · Cited by 71
“Targets (2008) 12(6) disease showed no overall toxicity in all patients and clinical benefit in some patients [87,88] .”
BackgroundCarbonic anhydrase inhibitors: Inhibition of the new membrane-associated isoform XV with phenols
Innocenti, A., Hilvo, M., Scozzafava, A., Parkkila, S., & Supuran, C. T. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.04.077 · Cited by 65
Clioquinol and docosahexaenoic acid act synergistically to kill tumor cells
Ding, W., Liu, B., Vaught, J. L., Palmiter, R. D., & Lind, S. E. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0067 · Cited by 66
“Forward primer (3-25), 5-TACCGAGCTCTTACGCGTGCTAG-3; reverse primer (379-357), 5-GCAATTGTTCCAGGAACCAGGGC-3.”
BackgroundZinc-binding compounds induce cancer cell death via distinct modes of action
Ding, W., Yu, H., & Lind, S. E. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.06.011 · Cited by 64
Repurposing old drugs as new inhibitors of the ubiquitin-proteasome pathway for cancer treatment
Yang, H., Chen, X., Li, K., Cheaito, H. A., Yang, Q., Wu, G., Liu, J., & Dou, Q. P. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.013 · Cited by 65
“CQ has been used for the treatment of neurodegerative disease [43-45].”
MethodKrawczyk, M., Pastuch-Gawołek, G., Mrozek‐Wilczkiewicz, A., Kuczak, M., Skonieczna, M., & Musioł, R. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.11.047 · Cited by 71
Metal-protein attenuating compounds and Alzheimer’s disease
Ritchie, C. W., Bush, A. I., & Masters, C. L. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.12.1585 · Cited by 62
“Clinical studies with clioquinol The earliest work investigating the use of clioquinol in Alzheimer’s disease was conducted in Sweden [26].”
BackgroundKarthik, R., Kumar, J. V., Chen, S., Seerangan, K., Karuppiah, C., Chen, T.-W., & Muthuraj, V. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b06851 · Cited by 59
Solfrizzi, V., Colacicco, A. M., D'Introno, A., Capurso, C., Parigi, A. D., Capurso, S. A., Torres, F., Capurso, A., & Panza, F. (2006) · Journal of Alzheimer's Disease · doi:10.3233/jad-2006-102-314 · Cited by 60
“Moreover, a mild cognitive improvement has been reported for a small-scale open study of 30 AD patients following a 3 week treatment regime with another metal-complexingagent-clioquinol[236].”
Wang, T., Wang, C.-Y., Shan, Z.-Y., Teng, W.-P., & Wang, Z.-Y. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-111874 · Cited by 59
“The present data, together with previous studies [21, 25, 57], suggest that oral administration of CQ may be a useful therapeutic strategy for the treatment of AD.”
ResultBehind the curtain of tauopathy: a show of multiple players orchestrating tau toxicity
Huang, Y., Wu, Z., & Zhou, B. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2042-8 · Cited by 59
“A small AD clinical study suggested clioquinol may be somewhat effective in treating the disease [257]; however, some of the results were also the subject of debate [258].”
The oxidative neurotoxicity of clioquinol
Benvenisti‐Zarom, L., Chen, J., & Regan, R. F. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.04.023 · Cited by 65
Pharmacotherapeutic targets in Alzheimer's disease
Biran, Y., Masters, C. L., Barnham, K. J., Bush, A. I., & Adlard, P. A. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00595.x · Cited by 57
“It also influenced CSF- , lowered plasma A 1–42 with no change to CSF-A 1–42 levels [419].”
BackgroundTherapeutic targets of brain insulin resistance in sporadic Alzheimer s disease
Monte, S. M. D. L. (2012) · Frontiers in Bioscience · doi:10.2741/e482 · Cited by 58
Zinc diet and Alzheimer's disease: a systematic review
Loef, M., von Stillfried, N., & Walach, H. (2012) · Nutritional Neuroscience · doi:10.1179/1476830512y.0000000010 · Cited by 56
Green, D. E., Bowen, M. L., Scott, L. E., Storr, T., Merkel, M., Böhmerle, K., Thompson, K. H., Patrick, B. O., Schugar, H. J., & Orvig, C. (2010) · Dalton Transactions · doi:10.1039/b918439b · Cited by 58
The Anti-neurodegeneration Drug Clioquinol Inhibits the Aging-associated Protein CLK-1
Wang, Y., Branicky, R. S., Stepanyan, Z., Carroll, M., Guimond, M.-P., Hihi, A. K., Hayes, S. T., McBride, K., & Hekimi, S. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m807579200 · Cited by 54
Liu, Y., Chen, Z., Song, X., Peng, Y., Qin, Q., & Liang, H. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.11.001 · Cited by 56
The link between cholesterol and Alzheimer's disease
Sjögren, M., & Blennow, K. (2005) · The World Journal of Biological Psychiatry · doi:10.1080/15622970510029795 · Cited by 56
“There is also support for beneficial effects, although minor, of clioquinol in the treatment of AD patients (Regland et al. 2001; Ritchie et al. 2003).”
ResultSelf-citationReversion of age-related recognition memory impairment by iron chelation in rats
de Lima, M. N. M., Dias, C. P., Torres, J. P., Dornelles, A. D. S., Garcia, V. A., Scalco, F. S., Guimarães, M. R., Petry, R. C., Bromberg, E., Constantino, L. D. S., et al. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.02.006 · Cited by 61
Braidy, N., Guillemin, G., & Grant, R. (2008) · Neurotoxicity Research · doi:10.1007/bf03033501 · Cited by 54
Wang, G., Hu, W., Tang, Q., Wang, L., Sun, X., Chen, Y., Yin, Y., Xue, F., & Sun, Z. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9302-3 · Cited by 57
High cytotoxicity of dihalo-substituted 8-quinolinolato-lanthanides
Chen, Z., Song, X., Peng, Y., Hong, X., Liu, Y., & Liang, H. (2011) · Dalton Transactions · doi:10.1039/c0dt01310b · Cited by 53
Intranasal delivery of deferoxamine reduces spatial memory loss in APP/PS1 mice
Hanson, L. R., Fine, J. M., Renner, D. B., Svitak, A. L., Burns, R. B., Nguyen, T. M., Tuttle, N. J., Marti, D. L., Panter, S. S., & Frey, W. H. (2012) · Drug Delivery and Translational Research · doi:10.1007/s13346-011-0050-2 · Cited by 55
“clioquinol may have resulted in mild improvements in cognition and neuropathology [18, 19]; however, its efficacy has been questioned [20] and some toxic effects have been”
Background
Metadata
- Authors
- Regland, B., Lehmann, W., Abedini, I., Blennow, K., Jonsson, M., Karlsson, I., Sjögren, M., Wallin, A., Xilinas, M., & Gottfries, C.-G.
- Affiliations
- Sahlgrenska University Hospital (SE)
- Venue
- Dementia and Geriatric Cognitive Disorders
- Publisher
- S. Karger AG
- Published
- 2001
- Volume
- 12
- Issue
- 6
- Pages
- 408-414
- ISSN
- 1420-8008 (ISSN-L)
- 1421-9824
- OpenAlex
- W2079722596
- Cited by
- 220
- References
- 30
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 3 · 2023: 2 · 2022: 6 · 2021: 8 · 2020: 8 · 2019: 5 · 2018: 6 · 2017: 8 · 2016: 4 · 2015: 10 · 2014: 9 · 2013: 4 · 2012: 20
- FWCI
- 7.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Dementia and Geriatric Cognitive Disorders (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Nursing › Nutrition and Dietetics › Trace Elements in Health
- Keywords
- Alzheimer's disease, clioquinol, metal chelation, zinc, copper, blood-brain barrier, amyloid plaques, cerebrospinal fluid, tau protein, GAP-43, serum copper, copper/zinc ratio, clinical improvement
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Chelating Agents, Copper, Dose-Response Relationship, Drug, Female, Humans, Clioquinol, Male, Middle Aged, Zinc, Chelation Therapy, tau Proteins, Treatment Outcome, GAP-43 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.